MedTrace Logo

Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus

NCT02518789 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2015-08-10

No results posted yet for this study

Summary

By observing the difference of plasma homovanillic acid concentrations and brain electrical consciousness monitoring Narcotrend index, study the possible mechanism of influencing Etomidate induced myoclonus with Dexmedetomidine pretreatment during general anesthesia induction period.

Conditions

  • Myoclonus

Interventions

DRUG

Low-dose Dexmedetomidine

Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.

DRUG

High-dose dexmedetomidine

Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.

DRUG

normal saline

Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.

DRUG

Etomidate

After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg. -Does not offer any other drugs within 5 min after completion of etomidate.

DRUG

midazolam，fentanyl，rocuronium

Anesthesia induction：Intravenous injection midazolam 0.03 \~ 0.05 mg/kg, fentanyl 5 \~ 8 g/kg, rocuronium 0.6 mg/kg

DRUG

propofol，remifentanil，cis atracurium

Anesthesia maintenance：Intravenous infusion of propofol 4 \~ 6 mg/kg/h, remifentanil 0.1 \~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \~ 0.1mg/kg

Sponsors & Collaborators

  • Tang-Du Hospital

    lead OTHER

Principal Investigators

  • LI yumin, PHD · Air Force Military Medical University, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-08-31
Completion
2016-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02518789 on ClinicalTrials.gov